Compare ADMA Biologics Inc (ADMA) vs Comcast Corporation (CMCSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Comcast Corporation — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Comcast Corporation trades at $23.6 (market cap $83.63B). The key difference: Comcast Corporation is far larger — about 39.3× ADMA Biologics Inc's market cap, and Comcast Corporation pays a 5.64% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CMCSA | |
|---|---|---|
Market Cap | $2.13B | $83.63B |
Sector | Health | Media |
52-Week High | $20.38 | $34.01 |
52-Week Low | $7.60 | $22.32 |
Enterprise Value | $2.20B | $168.77B |
Dividend Yield | — | 5.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
CMCSA trades at $23.41, down 1.6% over 24 hours, with a bearish technical signal but strong fundamentals including a low P/E of 4.66 and net income margin of 15%. Recent news highlights the planned spin-off of NBCUniversal and Sky's acquisition of ITV's media unit for $2.14 billion, signaling strategic refocusing on broadband infrastructure.
The stock appears undervalued with a consensus price target of $31.07, offering 33% upside, but faces risks from execution of corporate restructuring and pay-TV decline. Positive earnings beats and robust cash flow support a favorable outlook, though investor sentiment is mixed amid spin-off uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
